JP Morgan Chase’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.05M Hold
9,200
– – ﹤0.01% 4239
2026
Q2
$1.83M Hold
9,200
– – ﹤0.01% 4253
2026
Q1
$2.02M Hold
9,200
– – ﹤0.01% 4089
2025
Q4
$2.22M Hold
9,200
– – ﹤0.01% 3998
2025
Q3
$2.52M Hold
9,200
– – ﹤0.01% 3904
2025
Q2
$2.37M Buy
+9,200
New +$2.19M ﹤0.01% 3775
2025
Q1
– Sell
-2,500
Closed -$572K – 7663
2024
Q4
$572K Buy
+2,500
New +$602K ﹤0.01% 4973
2024
Q3
– Sell
-1,200
Closed -$230K – 7635
2024
Q2
$230K Hold
1,200
– – ﹤0.01% 5096
2024
Q1
$238K Buy
+1,200
New +$220K ﹤0.01% 5257
2014
Q4
– Sell
-90,000
Closed -$4.43M – 4335
2014
Q3
$4.43M Buy
+90,000
New +$4.58M ﹤0.01% 2441

Other funds holding RMD

JP Morgan Chase's RMD Position: Q3 2026 in Review

JP Morgan Chase reduced its ResMed (RMD) stake by 18% in Q3 2026, selling an estimated $33.6M and leaving 679,628 shares worth $151M. The position accounts for 0.01% of the portfolio, ranked #857.

JP Morgan Chase first reported a position in RMD in Q2 2013 and has held it in 54 quarters since. The position peaked at $306M in Q4 2020. 886 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

  • JP Morgan Chase held 679,628 shares of ResMed worth $151M as of Q3 2026.
  • JP Morgan Chase sold 153,908 ResMed shares in Q3 2026, an estimated $33.6M.
  • ResMed made up 0.01% of JP Morgan Chase's portfolio in Q3 2026, its #857 holding.
  • JP Morgan Chase first reported a position in ResMed in Q2 2013 and has held it in 54 quarters since.
  • JP Morgan Chase's ResMed position peaked at $306M in Q4 2020.
  • 886 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.